Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 156-162

  Inoue, Tomoko ^a   Osada, Kenichi ^b   Tagawa, Masaaki ^a   Ogawa, Yuriko ^b   Haga, Toshiaki ^b   Sogame, Yoshihisa ^a,c   Hashizume, Takanori ^a,d   Watanabe, Takashi ^b   Taguchi, Atsushi ^b   Katsumata, Takashi ^a   Yabuki, Masashi ^a   Yamaguchi, Noboru ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SUMITOMO CHEMICAL CO LTD   (Japan)

^d OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

Blonanserin; Knockout mice; P gp; P gp mediated DDI; Risperidone

Indexed keywords

BLONANSERIN; COMPLEMENTARY DNA; GLYCOPROTEIN P; PALIPERIDONE; RISPERIDONE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; CELL LINE, TRANSFORMED; HUMANS; ISOXAZOLES; LLC-PK1 CELLS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; P-GLYCOPROTEIN; PIPERAZINES; PIPERIDINES; PYRIMIDINES; RISPERIDONE; SWINE;

EID: 84864499997     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.06.005     Document Type: Article

References (30)

1. Adachi Y., Suzuki H., Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 2001, 18:1660-1668.
2. Borison R.L., Diamond B., Pathiraja A., Meibach R.C. Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 1994, 30:193-197.
3. Chen C., Liu X., Smith B.J. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 2003, 4:272-291.
4. Chinn L.W., Kroetz D.L. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007, 81:265-269.
5. Deeks E.D., Keating G.M. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 2010, 24:65-84.
6. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005, 33:165-174.
7. Feng B., Mills J.B., Davidson R.E., Mireles R.J., Janiszewski J.S., Troutman M.D., et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008, 36:268-275.
8. Garcia E., Robert M., Peris F., Nakamura H., Sato N., Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009, 23:615-625.
9. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9:215-236.
10. Heykants J., Huang M.L., Mannens G., Meuldermans W., Snoeck E., Van Beijsterveldt L., et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994, 55(Suppl.):13-17.
11. Kasai H., Hashimoto T., Yamada M., Sakai H., Handa J., Takazawa T., et al. Method of AUC estimation from sparse sampling data. Xenobiot Metabol Dispos 2001, 16:253-257.
12. Kim K.A., Park P.W., Liu K.H., Kim K.B., Lee H.J., Shin J.G., et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 2008, 48:66-72.
13. Kimura Y., Morita S.Y., Matsuo M., Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 2007, 98:1303-1310.
14. Kinoshita T. Long-term clinical study of blonanserin for schizophrenia-a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study). Jpn J Clin Psychopharmacol 2008, 11:135-153.
15. Mannens G., Meuldermans W., Snoeck E., Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 1994, 114:566-572.
16. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994, 151:825-835.
17. Miller D.S., Bauer B., Hartz A.M. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 2008, 60:196-209.
18. Miura S. Clinical evaluation of blonanserin for schizophrenia - a randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol 2008, 11:297-314.
19. Miyake N., Miyamoto S., Takeuchi A., Yamada S., Tadokoro M., Osako N., et al. Effect of new-generation antipsychotics blonanserin on cognitive impairment in schizophrenia: a randomized double-blind comparison with risperidone. Jpn J Clin Psychopharmacol 2008, 11:315-326.
20. Murasaki M. Clinical evaluation of blonanserin for schizophrenia - a randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 2007, 10:2059-2079.
21. Murasaki M., Nishikawa H., Ishibashi T. Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Jpn J Clin Psychopharmacol 2008, 11:845-854.
22. Nakagami T., Yasui-Furukori N., Saito M., Tateishi T., Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005, 78:43-51.
23. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 2006, 3:3-25.
24. Shin J.K., Malone D.T., Crosby I.T., Capuano B. Schizophrenia: a systematic review of the disease state, current therapeutics and their molecular mechanisms of action. Curr Med Chem 2011, 18:1380-1404.
25. 2A activity. Hum Psychopharmacol Clin Exp 2010, 25:342-346.
26. United State Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry Drug Interaction Studies - Study Design, Data analysis, Implications for Dosing, and Labeling Recommendations (draft guidance) 2012.
27. Wang J.S., Ruan Y., Taylor R.M., Donovan J.L., Markowitz J.S., DeVane C.L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004, 7:415-419.
28. Yamazaki M., Neway W.E., Ohe T., Chen I., Rowe J.F., Hochman J.H., et al. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001, 296:723-735.
29. Yang J., Bahk W.M., Cho H.S., Jeon Y.W., Jon D.I., Jung H.Y., et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 2010, 33:169-175.
30. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.